Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A DNA Vaccine Encoding the Gn Ectodomain of Rift Valley Fever Virus Protects Mice via a Humoral Response Decreased by DEC205 Targeting.

Chrun T, Lacôte S, Urien C, Richard CA, Tenbusch M, Aubrey N, Pulido C, Lakhdar L, Marianneau P, Schwartz-Cornil I.

Front Immunol. 2019 Apr 25;10:860. doi: 10.3389/fimmu.2019.00860. eCollection 2019.

2.

Antibody Fragments Humanization: Beginning with the End in Mind.

Aubrey N, Billiald P.

Methods Mol Biol. 2019;1904:231-252. doi: 10.1007/978-1-4939-8958-4_10.

PMID:
30539473
3.

Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.

Aubrey N, Allard-Vannier E, Martin C, Bryden F, Letast S, Colas C, Lakhrif Z, Collinet N, Dimier-Poisson I, Chourpa I, Viaud-Massuard MC, Joubert N.

Bioconjug Chem. 2018 Nov 21;29(11):3516-3521. doi: 10.1021/acs.bioconjchem.8b00668. Epub 2018 Oct 25.

PMID:
30352511
4.

Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide.

Hervé-Aubert K, Allard-Vannier E, Joubert N, Lakhrif Z, Alric C, Martin C, Viaud-Massuard MC, Dimier-Poisson I, Aubrey N, Chourpa I.

Bioconjug Chem. 2018 May 16;29(5):1553-1559. doi: 10.1021/acs.bioconjchem.8b00091. Epub 2018 Mar 23.

PMID:
29553717
5.

Targeted Delivery of Toxoplasma gondii Antigens to Dendritic Cells Promote Immunogenicity and Protective Efficiency against Toxoplasmosis.

Lakhrif Z, Moreau A, Hérault B, Di-Tommaso A, Juste M, Moiré N, Dimier-Poisson I, Mévélec MN, Aubrey N.

Front Immunol. 2018 Feb 20;9:317. doi: 10.3389/fimmu.2018.00317. eCollection 2018.

6.

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.

Alric C, Hervé-Aubert K, Aubrey N, Melouk S, Lajoie L, Même W, Même S, Courbebaisse Y, Ignatova AA, Feofanov AV, Chourpa I, Allard-Vannier E.

J Nanobiotechnology. 2018 Feb 21;16(1):18. doi: 10.1186/s12951-018-0341-6.

7.

Screening the low molecular weight fraction of human serum using ATR-IR spectroscopy.

Bonnier F, Brachet G, Duong R, Sojinrin T, Respaud R, Aubrey N, Baker MJ, Byrne HJ, Chourpa I.

J Biophotonics. 2016 Oct;9(10):1085-1097. doi: 10.1002/jbio.201600015. Epub 2016 Aug 10.

8.

Generation of recombinant antibody fragments with toxin-neutralizing potential in loxoscelism.

Karim-Silva S, Moura Jd, Noiray M, Minozzo JC, Aubrey N, Alvarenga LM, Billiald P.

Immunol Lett. 2016 Aug;176:90-6. doi: 10.1016/j.imlet.2016.05.019. Epub 2016 Jun 7.

9.

Immunodetection of the "brown" spider (Loxosceles intermedia) dermonecrotoxin with an scFv-alkaline phosphatase fusion protein.

Jiacomini I, Silva SK, Aubrey N, Muzard J, Chavez-Olortegui C, De Moura J, Billiald P, Alvarenga LM.

Immunol Lett. 2016 May;173:1-6. doi: 10.1016/j.imlet.2016.03.001. Epub 2016 Mar 10.

10.

A method to confer Protein L binding ability to any antibody fragment.

Lakhrif Z, Pugnière M, Henriquet C, di Tommaso A, Dimier-Poisson I, Billiald P, Juste MO, Aubrey N.

MAbs. 2016;8(2):379-88. doi: 10.1080/19420862.2015.1116657. Epub 2015 Dec 18.

11.

Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

Alvarenga LM, Zahid M, di Tommaso A, Juste MO, Aubrey N, Billiald P, Muzard J.

Toxins (Basel). 2014 Aug 21;6(8):2541-67. doi: 10.3390/toxins6082541. Review.

12.

Diabody mixture providing full protection against experimental scorpion envenoming with crude Androctonus australis venom.

di Tommaso A, Juste MO, Martin-Eauclaire MF, Dimier-Poisson I, Billiald P, Aubrey N.

J Biol Chem. 2012 Apr 20;287(17):14149-56. doi: 10.1074/jbc.M112.348912. Epub 2012 Feb 28.

13.

Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential.

Zahid M, Loyau S, Bouabdelli M, Aubrey N, Jandrot-Perrus M, Billiald P.

Anal Biochem. 2011 Oct 15;417(2):274-82. doi: 10.1016/j.ab.2011.06.036. Epub 2011 Jul 2.

PMID:
21771576
14.

Grafting of protein L-binding activity onto recombinant antibody fragments.

Muzard J, Adi-Bessalem S, Juste M, Laraba-Djebari F, Aubrey N, Billiald P.

Anal Biochem. 2009 May 15;388(2):331-8. doi: 10.1016/j.ab.2009.02.035. Epub 2009 Mar 4.

PMID:
19268418
15.

[Recombinant antibodies: towards a new generation of antivenoms?].

Aubrey N, Muzard J, Juste M, Billiald P.

J Soc Biol. 2006;200(4):345-54. Review. French.

PMID:
17652970
16.

Neurohormonal activation in severe scorpion envenomation: correlation with hemodynamics and circulating toxin.

Nouira S, Elatrous S, Besbes L, Boukef R, Devaux C, Aubrey N, Elayeb M, Abroug F.

Toxicol Appl Pharmacol. 2005 Oct 15;208(2):111-6.

PMID:
16183384
17.

Direct vs. mediated effects of scorpion venom: an experimental study of the effects of a second challenge with scorpion venom.

Ouanes-Besbes L, El Atrous S, Nouira S, Aubrey N, Carayon A, El Ayeb M, Abroug F.

Intensive Care Med. 2005 Mar;31(3):441-6. Epub 2005 Jan 28.

PMID:
15678309
18.

Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments.

Aubrey N, Muzard J, Christophe Peter J, Rochat H, Goyffon M, Devaux C, Billiald P.

Toxicon. 2004 Mar 1;43(3):233-41.

PMID:
15033320

Supplemental Content

Loading ...
Support Center